questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Antigènes B7
Antigène CD274
Antigène CD274 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Antigène CD274
Immunohistochimie
Cancer du poumon
Cancer du sein
Lymphocytes T
Système immunitaire
Symptômes
5
Immunosuppression
Infections
Maladies auto-immunes
Cellules T
Réponse immunitaire
Infections
Tests cliniques
Symptômes
Prévention
5
Prévention
Expression génique
Mode de vie sain
Système immunitaire
Détection précoce
Gestion du cancer
Habitudes alimentaires
Expression génique
Traitements
5
Inhibiteurs de PD-1
Pembrolizumab
Thérapies immunologiques
Réponse immunitaire
Thérapie génique
Expression génique
Effets secondaires
Réactions auto-immunes
Efficacité des traitements
Profil immunitaire
Complications
5
Immunosuppression
Progression tumorale
Maladies auto-immunes
Infections chroniques
Résistance aux traitements
Thérapies immunologiques
Survie des patients
Pronostic
Complications
Traitement approprié
Facteurs de risque
5
Facteurs de risque
Antécédents de cancer
Tabagisme
Cancer du poumon
Obésité
Expression génique
Infections virales
Cellules immunitaires
Stress chronique
Réponse immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD274 : Questions médicales les plus fréquentes",
"headline": "Antigène CD274 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD274 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2025-02-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD274"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes B7",
"url": "https://questionsmedicales.fr/mesh/D060887",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes B7",
"code": {
"@type": "MedicalCode",
"code": "D060887",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.168"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD274",
"alternateName": "B7-H1 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D060890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Soldano Ferrone",
"url": "https://questionsmedicales.fr/author/Soldano%20Ferrone",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Haidong Dong",
"url": "https://questionsmedicales.fr/author/Haidong%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Hongwei Du",
"url": "https://questionsmedicales.fr/author/Hongwei%20Du",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Barbara Savoldo",
"url": "https://questionsmedicales.fr/author/Barbara%20Savoldo",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Gianpietro Dotti",
"url": "https://questionsmedicales.fr/author/Gianpietro%20Dotti",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Clostridioides difficile Colitis.",
"datePublished": "2023-12-26",
"url": "https://questionsmedicales.fr/article/38677819",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.suc.2023.11.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Clostridioides difficile infections].",
"datePublished": "2023-10-18",
"url": "https://questionsmedicales.fr/article/37850615",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Does clinician-initiated Clostridioides difficile testing improve outcomes of patients with Clostridioides Difficile infection?",
"datePublished": "2023-05-11",
"url": "https://questionsmedicales.fr/article/37758340",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajic.2023.02.017"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37096495",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013871.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clostridioides (Clostridium) difficile in adults with diarrhoea in Vietnam.",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37244476",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.anaerobe.2023.102741"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes B7",
"item": "https://questionsmedicales.fr/mesh/D060887"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène CD274",
"item": "https://questionsmedicales.fr/mesh/D060890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD274 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD274",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD274",
"description": "Comment diagnostiquer une expression anormale de CD274 ?\nQuels tests sanguins sont utilisés pour CD274 ?\nCD274 est-il associé à des biomarqueurs spécifiques ?\nQuels types de cancers montrent une surexpression de CD274 ?\nComment évaluer l'impact de CD274 sur le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD274",
"description": "Quels symptômes sont liés à une surexpression de CD274 ?\nCD274 influence-t-il les symptômes des maladies auto-immunes ?\nY a-t-il des symptômes spécifiques au cancer liés à CD274 ?\nComment CD274 affecte-t-il la réponse aux infections ?\nLes symptômes de CD274 sont-ils visibles cliniquement ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD274",
"description": "Peut-on prévenir l'expression de CD274 ?\nComment un mode de vie sain influence-t-il CD274 ?\nY a-t-il des vaccins ciblant CD274 ?\nLa détection précoce des cancers aide-t-elle à gérer CD274 ?\nLes habitudes alimentaires influencent-elles CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD274",
"description": "Quels traitements ciblent CD274 ?\nComment les thérapies immunologiques agissent-elles sur CD274 ?\nCD274 peut-il être une cible pour la thérapie génique ?\nQuels effets secondaires sont associés aux traitements ciblant CD274 ?\nLes traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD274",
"description": "Quelles complications sont liées à une surexpression de CD274 ?\nCD274 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de résistance aux traitements avec CD274 ?\nComment CD274 influence-t-il la survie des patients ?\nLes complications de CD274 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD274",
"description": "Quels facteurs augmentent le risque d'expression de CD274 ?\nLe tabagisme influence-t-il CD274 ?\nY a-t-il un lien entre l'obésité et CD274 ?\nLes infections virales affectent-elles CD274 ?\nLe stress chronique influence-t-il CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Clostridioides+difficile#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD274 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour CD274 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274."
}
},
{
"@type": "Question",
"name": "CD274 est-il associé à des biomarqueurs spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1."
}
},
{
"@type": "Question",
"name": "Quels types de cancers montrent une surexpression de CD274 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de CD274 sur le système immunitaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de CD274 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "CD274 influence-t-il les symptômes des maladies auto-immunes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Comment CD274 affecte-t-il la réponse aux infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections."
}
},
{
"@type": "Question",
"name": "Les symptômes de CD274 sont-ils visibles cliniquement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'expression de CD274 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il CD274 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins ciblant CD274 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274."
}
},
{
"@type": "Question",
"name": "La détection précoce des cancers aide-t-elle à gérer CD274 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD274 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CD274 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274."
}
},
{
"@type": "Question",
"name": "Comment les thérapies immunologiques agissent-elles sur CD274 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "CD274 peut-il être une cible pour la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont associés aux traitements ciblant CD274 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations."
}
},
{
"@type": "Question",
"name": "Les traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une surexpression de CD274 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une immunosuppression accrue et une progression tumorale."
}
},
{
"@type": "Question",
"name": "CD274 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements avec CD274 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques."
}
},
{
"@type": "Question",
"name": "Comment CD274 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer."
}
},
{
"@type": "Question",
"name": "Les complications de CD274 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'expression de CD274 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il CD274 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'obésité et CD274 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'obésité peut être associée à une expression accrue de CD274."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles CD274 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il CD274 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 10/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, SZ, China.
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, SZ, China.
SuZhou Bright Scistar Antibody Biotech co., Ltd, 303-305, Bldg 15, NO.8, Jinfeng Road, Suzhou, SZ, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: songguozheng2013@yahoo.com.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Royal Veterinary Collegegrid.20931.39, London, United Kingdom.
OIE/FAO International Reference Laboratory for Avian Influenza, Swine Influenza and Newcastle Disease, Animal and Plant Health Agency (APHA), Weybridge, Addlestone, Surrey, United Kingdom.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
Clostridioides difficile colitis is an important source of hospital-acquired diarrhea associated with antibiotic use. Symptoms are profuse watery diarrhea, typically following a course of antibiotics;...
Here, we describe the epidemiology, diagnostics, and treatment of...
Clostridioides difficile (C. difficile) is a common hospital-acquired infection which can lead to major implications for patients and our health care system. In this study, we examine a policy change ...
The time to receive results and initiate treatment were analyzed before and after the policy change, and between physicians and nurses using descriptive statistics and paired student t-tests. Variable...
The difference in time to obtain the result both before and after the policy change and between ordering provider type were both statistically significant (P < .05). In unadjusted models, nurses were ...
Allowing bedside nurses more autonomy to order the stool sample significantly decreased the amount of time to receive the results, potentially decreasing the risk of additional infections among patien...
Clostridioides difficile (formerly known as Clostridium difficile) is a bacterium that can cause potentially life-threatening diarrheal illness in individuals with an unhealthy mixture of gut bacteria...
To evaluate the benefits and harms of donor-based fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile infection in immunocompetent people....
We used standard, extensive Cochrane search methods. The latest search date was 31 March 2022....
We considered randomized trials of adults or children with rCDI for inclusion. Eligible interventions must have met the definition of FMT, which is the administration of fecal material containing dist...
We used standard Cochrane methods. Our primary outcomes were 1. proportion of participants with resolution of rCDI and 2. serious adverse events. Our secondary outcomes were 3. treatment failure, 4. a...
We included six studies with 320 participants. Two studies were conducted in Denmark, and one each in the Netherlands, Canada, Italy, and the US. Four were single-center and two were multicenter studi...
In immunocompetent adults with rCDI, FMT likely leads to a large increase in the resolution of recurrent Clostridioides difficile infection compared to alternative treatments such as antibiotics. Ther...
Clostridioides (Clostridium) difficile causes antimicrobial-associated diarrhoea, however, presentations may range from asymptomatic carriage to severe diarrhoea, life-threatening toxic megacolon and ...
Diarrhoeal stool samples from adult patients aged ≥17 years old were collected at Thai Binh General Hospital in northern Vietnam between March 1, 2021 and February 28, 2022. All samples were transport...
A total of 205 stool samples were collected from patients aged from 17 to 101 years old. The overall prevalence of C. difficile was 15.1% (31/205) with the recovery of toxigenic and non-toxigenic isol...
The prevalence of C. difficile in adults with diarrhoea and multidrug resistance in C. difficile isolates was relatively high. A clinical assessment to differentiate between CDI/disease and colonisati...
Clostridioides difficile is the leading health care-associated pathogen, leading to substantial morbidity and mortality; however, there is no widely accepted model to predict C. difficile infection se...
To investigate the epidemiology of Clostridioides difficile infection (CDI) in Slovakian hospitals after the emergence of ribotype 176 (027-like) in 2016....
Between 2018 and 2019, European Centre for Disease Control and Prevention CDI surveillance protocol v2.3 was applied to 14 hospitals, with additional data collected on recent antimicrobial use and the...
The mean hospital incidence of CDI was 4.1 cases per 10,000 patient bed-days. One hundred and five (27.6%) in-hospital deaths were reported among the 381 cases. Antimicrobial treatment within the prev...
The newly-predominant RT176 and endemic RT001 are driving the epidemiology of CDI in Slovakia. In addition to fluoroquinolones, the use of macrolide-lincosamide-streptogramin B antibiotics can represe...
Clostridioides difficile infection (CDI) is a significant worry within healthcare institutions and the community. It is one of the leading agents causing severe diarrhea worldwide. Effective managemen...
Clostridioides difficile infection (CDI) is the most common hospital acquired infection in the USA, with recurrence rates > 15%. Although primary CDI has been extensively linked to gut microbial dysbi...
We conducted a prospective, longitudinal study of 53 non-immunocompromised participants with primary CDI. Stool sample collection began pre-CDI antibiotic treatment at the time of diagnosis, and conti...
The prospective, longitudinal, and multi-omic nature of our CDI recurrence study allowed us to uncover previously unrecognized dynamics in the microbiome and host presaging recurrence, and, in particu...